Cargando…

Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial

BACKGROUND: Combining palbociclib with letrozole or fulvestrant improved progression-free survival in hormone receptor (HR)-positive and human epidermal growth factor receptor-negative metastatic breast cancer. However, combining palbociclib to endocrine treatment increases toxicity and cost compare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narui, Kazutaka, Ishikawa, Takashi, Taira, Naruto, Uemura, Yukari, Mukai, Hirofumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451568/ https://www.ncbi.nlm.nih.gov/pubmed/36128589 http://dx.doi.org/10.14740/wjon1507

Ejemplares similares

Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study
por: Ishikawa, Takashi, et al.
Publicado: (2021)

Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: Miyahara, Kana, et al.
Publicado: (2022)

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2019)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
por: Hagiwara, Yasuhiro, et al.
Publicado: (2017)

Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)

Palbociclib in breast cancer neoadjuvant setting
por: Duarte, Sílvia Alexandra Cabral, et al.
Publicado: (2021)

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
por: Tamura, Kenji, et al.
Publicado: (2016)

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
por: Im, Seock-Ah, et al.
Publicado: (2019)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Neutropenia due to palbociclib: A word of caution?
por: Pramanik, Raja, et al.
Publicado: (2016)

Palbociclib: COVID-19 infection: case report
Publicado: (2020)

Lysosomal trapping of palbociclib and its functional implications
por: Llanos, Susana, et al.
Publicado: (2019)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan—The KBCOG-14 Study
por: Odan, Nina, et al.
Publicado: (2020)

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study
por: Beachler, Daniel C., et al.
Publicado: (2021)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Translating palbociclib to the clinic for DIPG - What is truly achievable?
por: Franshaw, Laura, et al.
Publicado: (2019)

Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib
por: Nelson, Kellie Lynn, et al.
Publicado: (2017)

Early treatment-related neutropenia predicts response to palbociclib
por: McAndrew, Nicholas P., et al.
Publicado: (2020)

Exemestane/palbociclib/prednisolone: Various toxicities: case report
Publicado: (2020)

Population Pharmacokinetics of Palbociclib in a Real-World Situation
por: Royer, Bernard, et al.
Publicado: (2021)

Posterior Reversible Encephalopathy Occurring During Treatment With Palbociclib
por: Belaidi, Lahcene, et al.
Publicado: (2021)

Regression of choroidal metastasis from breast carcinoma with palbociclib
por: Parakh, Shweta, et al.
Publicado: (2022)

Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice
por: Alves da Costa, Filipa, et al.
Publicado: (2023)

Updates on managing advanced breast cancer with palbociclib combination therapy
por: McShane, Teresa M., et al.
Publicado: (2018)

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
por: Uras, Iris Z., et al.
Publicado: (2018)

Palbociclib-Induced Pneumonitis: A Case Report and Review of the Literature
por: Sarkisian, Saro, et al.
Publicado: (2020)

Acute Lymphoblastic Leukemia in a Patient Treated with Letrozole and Palbociclib
por: Park, Jin Hyun, et al.
Publicado: (2019)

The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma
por: Horbinski, Craig, et al.
Publicado: (2021)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Design, synthesis, and anticancer activity of three novel palbociclib derivatives
por: Li, Tian, et al.
Publicado: (2022)

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
por: Zhu, Zhou, et al.
Publicado: (2022)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study
por: Cardoso Borges, Fábio, et al.
Publicado: (2022)

Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial
por: Kawahara, Takuya, et al.
Publicado: (2022)

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tp8e9vt4p4p7hrmisc2b1f48ah